135 related articles for article (PubMed ID: 14650831)
1. Interleukin-2 based therapy for kidney cancer.
Dutcher JP
Cancer Treat Res; 2003; 116():155-72. PubMed ID: 14650831
[TBL] [Abstract][Full Text] [Related]
2. High-dose interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma: still the standard.
Dutcher JP
Oncology (Williston Park); 2011 Apr; 25(5):427-8. PubMed ID: 21710841
[No Abstract] [Full Text] [Related]
3. Update on the application of interleukin-2 in the treatment of renal cell carcinoma.
McDermott DF
Clin Cancer Res; 2007 Jan; 13(2 Pt 2):716s-720s. PubMed ID: 17255299
[TBL] [Abstract][Full Text] [Related]
4. Systemic chemotherapy and chemoimmunotherapy for metastatic renal cell cancer.
Heinzer H; Huland E; Huland H
World J Urol; 2001 Apr; 19(2):111-9. PubMed ID: 11374313
[TBL] [Abstract][Full Text] [Related]
5. Response of papillary renal cell carcinoma in a solitary kidney to high dose interleukin therapy.
Diner EK; Linehan M; Walther M
Int J Urol; 2005 Nov; 12(11):996-7. PubMed ID: 16351658
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-2 therapy of metastatic renal cell carcinoma: update of phase III trials.
McDermott DF; Regan MM; Atkins MB
Clin Genitourin Cancer; 2006 Sep; 5(2):114-9. PubMed ID: 17026799
[TBL] [Abstract][Full Text] [Related]
7. Improving the therapeutic index of IL-2.
McDermott DF
Clin Adv Hematol Oncol; 2010 Dec; 8(12):862-4. PubMed ID: 21326162
[No Abstract] [Full Text] [Related]
8. A review of recent findings involving interleukin-2-based cancer therapy.
Eklund JW; Kuzel TM
Curr Opin Oncol; 2004 Nov; 16(6):542-6. PubMed ID: 15627015
[TBL] [Abstract][Full Text] [Related]
9. Contemporary trends in high-dose interleukin-2 use for metastatic renal cell carcinoma in the United States.
Allard CB; Gelpi-Hammerschmidt F; Harshman LC; Choueiri TK; Faiena I; Modi P; Chung BI; Tinay I; Singer EA; Chang SL
Urol Oncol; 2015 Nov; 33(11):496.e11-6. PubMed ID: 26210683
[TBL] [Abstract][Full Text] [Related]
10. Cytokine therapy for metastatic renal cell carcinoma.
Bukowski RM
Semin Urol Oncol; 2001 May; 19(2):148-54. PubMed ID: 11354535
[TBL] [Abstract][Full Text] [Related]
11. The prognostic significance of stable disease following high-dose interleukin-2 (IL-2) treatment in patients with metastatic melanoma and renal cell carcinoma.
Hughes T; Klairmont M; Broucek J; Iodice G; Basu S; Kaufman HL
Cancer Immunol Immunother; 2015 Apr; 64(4):459-65. PubMed ID: 25603775
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-2 therapy of metastatic renal cell carcinoma--predictors of response.
McDermott DF; Atkins MB
Semin Oncol; 2006 Oct; 33(5):583-7. PubMed ID: 17045087
[TBL] [Abstract][Full Text] [Related]
13. [Cytokine therapy for metastatic renal cell carcinoma].
Eto M; Naito S
Gan To Kagaku Ryoho; 2002 Oct; 29(10):1738-44. PubMed ID: 12402423
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of sequential radiation and interleukin 2 in the treatment of patients with metastatic renal cell carcinoma.
Redman BG; Hillman GG; Flaherty L; Forman J; Dezso B; Haas GP
Clin Cancer Res; 1998 Feb; 4(2):283-6. PubMed ID: 9516912
[TBL] [Abstract][Full Text] [Related]
15. Interleukin 2 in cancer therapy.
Antony GK; Dudek AZ
Curr Med Chem; 2010; 17(29):3297-302. PubMed ID: 20712575
[TBL] [Abstract][Full Text] [Related]
16. Can outpatient interleukin-2 and interferon replace high-dose interleukin-2 for metastatic renal cell carcinoma?
Vieweg J
Nat Clin Pract Oncol; 2005 Apr; 2(4):192-3. PubMed ID: 16264932
[No Abstract] [Full Text] [Related]
17. Re: C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy.
Ramsey S; Aitchison M
J Urol; 2005 Dec; 174(6):2422-3. PubMed ID: 16280863
[No Abstract] [Full Text] [Related]
18. Administration of interleukin 12 with pulse interleukin 2 and the rapid and complete eradication of murine renal carcinoma.
Wigginton JM; Komschlies KL; Back TC; Franco JL; Brunda MJ; Wiltrout RH
J Natl Cancer Inst; 1996 Jan; 88(1):38-43. PubMed ID: 8847724
[TBL] [Abstract][Full Text] [Related]
19. Application of IL-2 and other cytokines in renal cancer.
McDermott DF; Atkins MB
Expert Opin Biol Ther; 2004 Apr; 4(4):455-68. PubMed ID: 15102596
[TBL] [Abstract][Full Text] [Related]
20. Is IL-2 still indicated for melanoma and RCC? What a question to ask!
Hamid O
Oncology (Williston Park); 2013 Jul; 27(7):695, 701. PubMed ID: 23977765
[No Abstract] [Full Text] [Related]
[Next] [New Search]